Hepatic Artery Injection of <sup>131</sup>I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34475235.
- Also identified by DOI 10.2967/jnumed.121.262136 and PMC identifier 8973296.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of <sup>131</sup>I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. <b>Methods:</b> Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with <sup>131</sup>I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. <b>Results:</b> The median time to tumor recurrence was 6 mo in the TACE + <sup>131</sup>I-metuximab group (<i>n</i> = 160) and 3 mo in the TACE group (<i>n</i> = 160) (hazard ratio, 0.55; 95% CI, 0.43-0.70; <i>P</i> < 0.001). The median overall survival was 28 mo in the TACE + <sup>131</sup>I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47-0.82; <i>P</i> = 0.001). <b>Conclusion:</b> TACE + <sup>131</sup>I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.
Medical subject headings
- Carcinoma, Hepatocellular
- Chemoembolization, Therapeutic
- Liver Neoplasms